INT8052

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 46
Total Number 49
Disease Relevance 13.73
Pain Relevance 2.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (COMP) extracellular region (COMP) cell adhesion (COMP)
proteinaceous extracellular matrix (COMP)
Anatomy Link Frequency
chondrocytes 6
Cartilage 3
ECM 2
blood 1
hip 1
COMP (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 252 99.84 Very High Very High Very High
imagery 64 99.84 Very High Very High Very High
cytokine 55 97.56 Very High Very High Very High
rapifen 1 97.20 Very High Very High Very High
Osteoarthritis 333 94.60 High High
Pain 44 91.28 High High
ketamine 11 85.52 High High
Inflammation 96 85.08 High High
Analgesic 1 83.72 Quite High
agonist 1 81.88 Quite High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 253 99.84 Very High Very High Very High
Targeted Disruption 224 99.80 Very High Very High Very High
Necrosis 18 99.60 Very High Very High Very High
Cancer 74 99.24 Very High Very High Very High
Stress 364 99.00 Very High Very High Very High
Death 142 98.44 Very High Very High Very High
Aging 30 97.88 Very High Very High Very High
Osteoarthritis 278 94.60 High High
Chondrosarcoma 336 94.52 High High
Congenital Anomalies 85 93.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Consistent with our recombinant COMP expression results, shRNA 3B was the most effective at reducing endogenous COMP mRNA levels, a 99% reduction.
Negative_regulation (reducing) of COMP mRNA
1) Confidence 0.58 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0 Pain Relevance 0
Therefore, long-term knock down of COMP is necessary to suppress PSACH and MED/EDM1 cellular phenotype.
Negative_regulation (suppress) of PSACH associated with targeted disruption
2) Confidence 0.58 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.46 Pain Relevance 0
In these experiments, we sought to determine if reduction of COMP mRNA by shRNA would reduce ER stress by assessing CRT as a measure of ER stress in COS-7 cells.
Negative_regulation (reduction) of COMP mRNA associated with stress
3) Confidence 0.58 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.45 Pain Relevance 0
At time point 24 weeks, serum COMP levels decreased after one hour of rest in both groups, p = 0.002 in exercise group and p = 0.004 in control group, in a similar manner as at time point – 3 weeks.
Negative_regulation (decreased) of COMP
4) Confidence 0.51 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1712338 Disease Relevance 0 Pain Relevance 0
This result demonstrates that reduction of intracellular MT-COMP by RNAi normalizes the export of the other matrix proteins preventing the premature protein interactions and intracellular matrix assembly.
Negative_regulation (reduction) of MT-COMP
5) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.27 Pain Relevance 0
In comparison, shRNA 3B reduction of MT-COMP also reduced the retention of other ECM proteins retained (Fig. 7 right panel).
Negative_regulation (reduction) of MT-COMP
6) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.22 Pain Relevance 0
All together we show RNAi was effective at reducing high levels of COMP and remains effective over time.


Negative_regulation (reducing) of COMP
7) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.12 Pain Relevance 0
These results demonstrate that targeting the type 3 repeat domain was more effective at reducing COMP than targeting the globular domain.


Negative_regulation (reducing) of COMP
8) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.30 Pain Relevance 0
Taken together, these results suggest that reducing mutant COMP mRNA levels may dampen the ER stress and matrix formation in the rER that is potentiated by the presence of mutant COMP.
Negative_regulation (reducing) of mutant COMP associated with stress
9) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.41 Pain Relevance 0
These results suggest that reducing intracellular COMP via knock down of COMP mRNA lessens ER stress.


Negative_regulation (reducing) of COMP associated with stress and targeted disruption
10) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.88 Pain Relevance 0
Serum measurements showed a significant decrease in COMP and Aggrecan concentrations over time in both groups, but no difference was found between groups at T1, where the Ex group had already completed the exercise protocol (Figure 4).
Negative_regulation (decrease) of COMP
11) Confidence 0.46 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945016 Disease Relevance 0.07 Pain Relevance 0.08
As shown in shown in Fig. 6, all four of the shRNAs reduced endogenous human COMP mRNA levels by at least 80%.
Negative_regulation (reduced) of COMP mRNA
12) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.05 Pain Relevance 0
Surprisingly, mice lacking COMP have only minor skeletal anomalies, suggesting that absence of COMP is not detrimental to morphogenesis and skeletal development [16].
Negative_regulation (absence) of COMP
13) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.79 Pain Relevance 0.06
Two shRNA integrants of 3B (3B-1 and 3B-2) reduced COMP mRNA and protein levels to less than 10% of the control compared to integrants of shRNA 3A (3A A–I) that only reduced COMP to approximately 30% of the control.
Negative_regulation (reduced) of COMP mRNA
14) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.12 Pain Relevance 0
We tested this hypothesis using RNA interference to reduce steady state levels of COMP mRNA.
Negative_regulation (reduce) of COMP mRNA
15) Confidence 0.43 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2858657 Disease Relevance 0.42 Pain Relevance 0
Moreover, we show that reducing steady state levels of COMP mRNA alleviates intracellular retention of other extracellular matrix proteins associated with the pseudoachondroplasia cellular pathology.
Negative_regulation (reducing) of COMP mRNA in extracellular matrix
16) Confidence 0.43 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2858657 Disease Relevance 0.39 Pain Relevance 0
We next tested the efficacy of shRNAs to reduce endogenous COMP mRNA levels in human chondrocytes.
Negative_regulation (reduce) of COMP mRNA in chondrocytes
17) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.06 Pain Relevance 0
As shown in Fig. 2, COMP mRNA (A and B) and protein (C and D) were markedly reduced by two shRNAs, 3A and 3B, that target different COMP type 3 calcium-repeat domain sequences (Fig. 1).
Negative_regulation (reduced) of COMP mRNA
18) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.17 Pain Relevance 0
We show that COMP mRNA and protein levels can be significantly decreased by shRNAs directed against the COMP type 3 repeat domain.
Negative_regulation (decreased) of COMP mRNA
19) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.27 Pain Relevance 0
By 2 days shRNA 3B reduced COMP protein levels by 90%, and COMP expression was not detectable after 4 days of culture (Fig. 4*) (only MT-COMP results are shown in Fig. 4 because WT-COMP knock down was identical). shRNA 3A was approximately three times less efficient than 3B at reducing COMP protein levels.
Negative_regulation (reducing) of COMP protein associated with targeted disruption
20) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.50 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox